Global Procalcitonin Antibody Industry Research Report, Growth Trends and Competitive Analysis 2021-2027

Procalcitonin (PCT) is a 116 amino acid residue protein with a molecular weight of approximately 13kDa. Procalcitonin is a peptide hormone mainly produced by the C cells of the thyroid and certain endocrine cells of the lung. Under normal expression conditions, procalcitonin is immediately cleaved into three specific fragments, an N terminal residue, calcitonin and katacalcin. It can be expressed in E. coli.Procalcitonin Antibody refers to the specific protein which can qualitatively and quantitatively detect the PCT level. PCT level is a parameter for the diagnosis and monitoring of bacterial inflammatory diseases
Sepsis is a life-threatening organ dysfunction caused by an excessive host immune response to a serious infection. According to the Centers for Disease Control and Prevention (CDC), 1.6 million Americans suffered from sepsis in 2011, of which about 260,000 did not survive. PCT can play a critical role in addressing this clinical challenge and has become a key component of successful sepsis protocols across the U.S. and Europe. PCT levels increase precipitously in patients with severe bacterial infection. PCT is therefore an extremely important biomarker enabling specific differentiation between a severe bacterial infection and other causes of inflammatory reactions.
The technical barriers of procalcitonin antibody are high and the procalcitonin antibody production concentrated large companies including Thermo Fisher, Roche Diagnostics, bioMerieux, HyTest, etc. The sales revenue of top five manufacturers accounted for 37.9% in 2016. Thermo Fisher is the largest manufacturer in the world, which sales reached 2.48g in China.
The manufacture region is concentrated in South China, East China and Southwest China, of which East China is the largest region with the share 24.28% in 2016. The sales shares of Southwest China and South China were 15.59% and 14.79%.
There are companies adding new capacities and aims at the cost and quality leadership which shall improve profitability. As the same time, companies are focusing on technological innovation, equipment upgrades, and process improvements, to reduce costs and improve quality. The competition in procalcitonin antibody market will become more intense.

In 2020, the global Procalcitonin Antibody market size was US$ XX million and is forecast to XX million US in 2027, growing at a CAGR of XX% during the 2021-2027. In this study, 2020 has been considered as the base year and 2021 to 2027 as the forecast period to estimate the market size for Procalcitonin Antibody.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Procalcitonin Antibody market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Procalcitonin Antibody market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Procalcitonin Antibody market. Readers of the report can become informed about current and future trends of the global Procalcitonin Antibody market and how they will impact market growth during the forecast period.

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Segment by Type
Polyclonal Procalcitonin Antibody
Monoclonal Procalcitonin Antibody

Segment by Application
Hospital
Medical research institutions
Others

By Company
Thermo Fisher
Roche Diagnostics
bioMerieux
HyTest
Wondfo
Ningbo Medicalsystem Biotechnology
Snibe
Vazyme Biotech
Getein Biotech
Hotgen Biotech
Lumigenex
Shanghai Medicine'nest Pharmaceutical
Kitgen
Beijing KeyGen
Fantibody

Frequently Asked Questions